A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for preliminary anti-tumor activity in these tumor types. The MTD was initially defined as 113 mg CPT equivalents(eq)/m2 in the dose escalation part of the study. However, in the initial expansion phase (Protocol Amendment 11), 11 patients (10 NSCLC patients and 1 gastric cancer patients) were dosed at 113 mg CPT eq/m2 and less bone marrow toxicity was observed as compared to more heavily pre-treated patients in the dose escalation part of the study. Therefore, this amended expansion phase will investigate the safety and anti-tumor effects of a dose of 150 mg CPT eq/m2.

The study will also determine:

• The safety and tolerability of XMT-1001 at 150 mg CPT eq/m2
• The pharmacokinetics (PK) of XMT-1001 (how XMT-1001 behaves in the body) in patients Stage IV non-small cell lung carcinoma (NSCLC) and small cell lung cancer
• Evidence of XMT-1001 anti-tumor activity at 150 mg CPT eq/m2

Study Overview

• Status: Completed
• Conditions: Small Cell Lung Cancer; Non-small Cell Lung Cancer
• Intervention / Treatment: Drug: XMT-1001

Detailed Description

This is an open-label study of XMT-1001 administered intravenously over 4 hours every 21 days (1 Cycle). Blood sampling for PK analyses will be performed immediately prior to dosing, and 9 times after dosing. Patients will be assessed for toxicities known to occur with other drugs of this class, such as bone marrow suppression, elevated liver function enzymes, hemorrhagic cystitis, and diarrhea. Tumor imaging will be performed every 2 cycles.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85258
      • TGen Clinical Research Services at Scottsdale Healthcare
  • Colorado
    • Denver, Colorado, United States, 80218
      • Rocky Mountain Cancer Centers
  • Indiana
    • Indianapolis, Indiana, United States, 46219
      • Central Indiana Cancer Centers
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • University of Maryland, Greenebaum Cancer Center
  • Nevada
    • Las Vegas, Nevada, United States, 89169
      • Comprehensive Cancer Centers of Nevada
  • New York
    • New York, New York, United States, 12208
      • New York Oncology Hematology
  • Oregon
    • Springfield, Oregon, United States, 97477
      • Willamette Valley Cancer Institute and Research Center
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Institute of Translational Oncology Research
  • Texas
    • Tyler, Texas, United States, 75702
      • Texas Oncology - Tyler
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Virginia Oncology Associates
  • Washington
    • Spokane, Washington, United States, 99218
      • Evergreen Hematology & Oncology
    • Vancouver, Washington, United States, 98684
      • Vancouver Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. At least 18 years old

2. Have histological or cytological documentation of one of the following:

   A. NSCLC with Stage IV disease according to the American Joint Cancer Commission TNM Staging (7th Edition)

   • Have received at least one prior chemotherapy regimen but no more than two chemotherapy regimens for their advanced disease (not containing irinotecan or topotecan).
   • Adjuvant chemotherapy will be considered as a prior chemotherapy regimen only if it is completed less than 6 months prior to enrollment.
   • Treatment with erlotinib or crizotinib as single agents will not be considered as a chemotherapy regimen for purposes of this trial OR B. SCLC with Stage IV (extensive) or recurrent disease after definitive treatment for limited stage disease according to the American Joint Cancer Commission TNM Staging (7th Edition)1
   • Have received at least one prior chemotherapy regimen but no more than two chemotherapy regimens for their advanced disease (not containing irinotecan or topotecan).
   • Adjuvant chemotherapy will be considered as a prior chemotherapy regimen only if it is completed less than 6 months prior to enrollment.
3. Patients must be refractory or resistant to standard therapy or for whom standard therapy is not anticipated to be curative and who have progressed through prior regimens.
4. Patients must have measurable disease with at least one lesion that can be accurately measured by Response Evaluation Criteria in Solid Tumors (RECIST). The lesion size must be ≥20 mm by conventional radiological techniques or ≥10 mm by spiral CT scan. Disease in an irradiated field as the only site of measurable disease is acceptable if there has been a clear progression of the lesion. PET scans are not suitable for providing these measurements. For patients who are sensitive to contrast, MRI may be used.
5. Patients with CNS metastases are acceptable provided that the disease has been treated (e.g. surgery, whole brain radiotherapy, stereotactic radiotherapy etc.) and the patient is stable for at least two weeks and does not require steroids (at least one week off steroids). Anti-seizure medication is allowed at the discretion of the treating physician.
6. At least 42 days since administration of mitomycin or nitrosoureas, and 28 days since any other chemotherapy, investigational agent, and/or radiation therapy.

7. Have the following laboratory values:

   • Absolute neutrophil count (ANC) ≥1500 cells/mm3
   • Platelet count >100,000 cells/mm3
   • Hemoglobin ≥9.0 g/dL
   • Adequate renal function (serum creatinine ≤2 mg/dL) and creatinine clearance ≥45 mL/min (Calculated by Cockroft and Gault method)
   • Adequate hepatic function (bilirubin ≤1.5 mg/dL)

   • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the institutional upper limit of normal (ULN, or

     • 5 times the ULN if liver metastases are present)
   • Albumin of >3.0 g/dL
   • PT and PTT ≤1.5 times the ULN
8. Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1.
9. Have a life expectancy of at least 3 months.
10. Have signed an informed consent form.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: XMT-1001; XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m^2, the next dose level is 30 mg/m^2, followed by dose levels: 50 mg/m^2, 80 mg/m^2, 120 mg/m^2, 150 mg/m^2, and 190 mg/m^2 until disease progressions or unacceptable side effects are experienced.	Drug: XMT-1001; XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.; Other Names: MER-1001

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Adverse Events	Every 7 days in each 21 day cycle

Secondary Outcome Measures

Outcome Measure	Time Frame
Tumor response	Every 2 cycles
Time to tumor progression	Every 2 cycles

Collaborators and Investigators

• Sponsor: Mersana Therapeutics
• Investigators: Principal Investigator: Edward Sausville, MD, University of Maryland Greenebaum Cancer Center; Principal Investigator: Glen J Weiss, MD, TGen Clinical Research Services at Scottsdale Healthcare; Principal Investigator: Lawrence Garbo, MD, New York Oncology Hematology; Principal Investigator: Allen Lee Cohn, MD, Rocky Mountain Cancer Centers; Principal Investigator: Paul R. Conkling, MD, Virginia Oncology Associates; Principal Investigator: William J Edenfield, MD, Institute for Translational Oncology Research; Principal Investigator: Donald A. Richards, MD, Texas Oncology - Tyler; Principal Investigator: John R. Caton, MD, Willamette Valley Cancer Institute and Research Center; Principal Investigator: David A. Smith, MD, Northwest Cancer Specialists - Vancouver Cancer Center; Principal Investigator: Hillary H. Wu, MD, Central Indiana Cancer Centers; Principal Investigator: Fadi Braiteh, MD, Comprehensive Cancer Centers of Nevada; Principal Investigator: Stephen Anthony, MD, Evergreen Hematology & Oncology

Publications and helpful links

General Publications

• Yurkovetskiy AV, Hiller A, Syed S, Yin M, Lu XM, Fischman AJ, Papisov MI. Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Mol Pharm. 2004 Sep-Oct;1(5):375-82. doi: 10.1021/mp0499306.

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2011
• Primary Completion (Actual): December 1, 2011
• Study Completion (Actual): December 1, 2011

Study Registration Dates

• First Submitted: April 1, 2007
• First Submitted That Met QC Criteria: April 1, 2007
• First Posted (Estimate): April 3, 2007

Study Record Updates

• Last Update Posted (Actual): January 31, 2018
• Last Update Submitted That Met QC Criteria: January 29, 2018
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: safety; NSCLC; cancer; non-small cell lung cancer; pharmacokinetics; Phase 1; small cell lung cancer; tumor; SCLC; maximum tolerated dose; XMT-1001; camptothecin; Fleximer; polymer
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma
• Other Study ID Numbers: MER-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No